Trever Bivona, MD, PhD
Professor
Medicine
School of Medicine

He is a cancer biologist who leads a research program focused on signal transduction and cancer genetics and the molecular basis of tumor initiation, evolution, and drug resistance. A major area of interest is the function and therapeutic targeting of oncogenic receptor tyrosine kinases (RTKs) such as EGFR and ALK as well as RAS GTPase signaling. A recent discovery and area of interest is the role of membraneless cytoplasmic biomolecular condensates formed by certain oncogenic RTKs in driving oncogenic signaling through RAS and other proteins to promote cancer. The overall goal of this research program is to understand the regulatory principles underlying cancer cell signaling and tumor evolution to improve cancer therapy and patient survival and quality of life. Dr. Bivona received a NIH Director’s New Innovator Award and is an elected member of the American Society for Clinical Investigation. Dr. Bivona is currently Principal Investigator of the NIH/NCI U54 Bay Area Drug Resistance and Sensitivity Center and is a Chan-Zuckerberg Biohub Senior Investigator.

• Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
  Communications biology 2023 Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA
• FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer.
  Research square 2023 Menon S, Breese MR, Lin YP, Allegakoen H, Perati S, Heslin A, Horlbeck MA, Weissman J, Sweet-Cordero EA, Bivona TG, Tulpule A
• FET fusion oncoproteins disrupt physiologic DNA repair networks in cancer.
  bioRxiv : the preprint server for biology 2023 Menon S, Breese MR, Lin YP, Allegakoen H, Perati S, Heslin A, Horlbeck MA, Weissman J, Sweet-Cordero EA, Bivona TG, Tulpule A
• 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
  Communications biology 2023 Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA
• GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma.
  JCI insight 2022 Morales J, Allegakoen DV, Garcia JA, Kwong K, Sahu PK, Fajardo DA, Pan Y, Horlbeck MA, Weissman JS, Gustafson WC, Bivona TG, Sabnis AJ
• Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
  JTO clinical and research reports 2022 Lara MS, Gubens MA, Bacaltos B, Daran L, Lim SL, Li T, Gandara DR, Bivona TG, Riess JW, Blakely CM
• AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
  Cancer discovery 2022 Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr …
• Quantitative Framework for Bench-to-Bedside Cancer Research.
  Cancers 2022 Zaman A, Bivona TG
• Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function.
  PLoS biology 2022 Bennett NK, Nakaoka HJ, Laurent D, Okimoto RA, Sei Y, Horvai AE, Bivona TG, Ten Hoeve J, Graeber TG, Nakamura K, Nakamura JL
• Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
  The Journal of clinical investigation 2022 Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O…
• Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution.
  Cell 2022 Yang D, Jones MG, Naranjo S, Rideout WM, Min KHJ, Ho R, Wu W, Replogle JM, Page JL, Quinn JJ, Horns F, Qiu X, Chen MZ, Freed-Pastor WA, McGinnis CS, Patterson DM, Gartner ZJ, Chow ED, Bivona TG, Chan …
• Understanding Drug Sensitivity and Tackling Resistance in Cancer.
  Cancer research 2022 Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD
• Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.
  Science translational medicine 2022 Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC
• Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
  The Journal of clinical investigation 2022 Manabe T, Bivona TG
• Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.
  Molecular oncology 2022 Pedraz-Valdunciel C, Giannoukakos S, Potie N, Giménez-Capitán A, Huang CY, Hackenberg M, Fernandez-Hilario A, Bracht J, Filipska M, Aldeguer E, Rodríguez S, Bivona TG, Warren S, Aguado C, Ito M, …
• Evolution of metastasis: new tools and insights.
  Trends in cancer 2021 Gui P, Bivona TG
• Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids.
  Journal of visualized experiments : JoVE 2021 Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG
• DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma.
  Molecular cancer 2021 Wu Q, Luo X, Terp MG, Li Q, Li Y, Shen L, Chen Y, Jacobsen K, Bivona TG, Chen H, Zeng R, Ditzel HJ
• Targeting AXL in NSCLC.
  Lung Cancer (Auckland, N.Z.) 2021 Zaman A, Bivona TG
• Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.
  Cell reports 2021 Zaman A, Wu X, Lemoff A, Yadavalli S, Lee J, Wang C, Cooper J, McMillan EA, Yeaman C, Mirzaei H, White MA, Bivona TG
• Inhibition of SHP2 as an approach to block RAS-driven cancers.
  Advances in cancer research 2021 Chou YT, Bivona TG
• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, …
• Stepwise evolution of therapy resistance in AML.
  Cancer cell 2021 Gui P, Bivona TG
• Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.
  Cell 2021 Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG
• Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.
  Science (New York, N.Y.) 2021 Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS
• Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
  Current opinion in chemical biology 2021 Kerr DL, Haderk F, Bivona TG
• Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis.
  Oncogenesis 2020 Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Hölzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Grüner BM, Bivona TG, Schramm A, Schuler M
• Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G.
  Cancer letters 2020 Liu J, Mayekar MK, Wu W, Yan M, Guan H, Wang J, Zaman A, Cui Y, Bivona TG, Choudhry H, Xing Q, Cao W
• Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
  Cell 2020 Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA…
• Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.
  Nature communications 2020 Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, …
• Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, …
• EGFR targeted therapy resistance: current status, challenges, and future outlook.
  Journal of thoracic disease 2020 Bivona TG
• Betacellulin drives therapy resistance in glioblastoma.
  Neuro-oncology 2020 Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA
• AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, Brekken RA, Baguley B, …
• Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy.
  Chronic diseases and translational medicine 2020 Zargar A, Chang S, Kothari A, Snijders AM, Mao JH, Wang J, Hernández AC, Keasling JD, Bivona TG
• Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, …
• BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.
  Cancers 2019 Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R
• Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
  Cell reports 2019 Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, …
• Targeting Oncogenic BRAF: Past, Present, and Future.
  Cancers 2019 Zaman A, Wu W, Bivona TG
• CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.
  The Journal of clinical investigation 2019 Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG
• Engineering Multidimensional Evolutionary Forces to Combat Cancer.
  Cancer discovery 2019 McCoach CE, Bivona TG
• Dampening oncogenic RAS signaling.
  Science (New York, N.Y.) 2019 Bivona TG
• Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
  Current oncology reports 2019 Halliday PR, Blakely CM, Bivona TG
• Polytherapy and Targeted Cancer Drug Resistance.
  Trends in cancer 2019 Chatterjee N, Bivona TG
• Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
  The Journal of experimental medicine 2019 Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, …
• Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
  Trends in molecular medicine 2019 Sabnis AJ, Bivona TG
• Immunohistochemistry to Study YAP in Human Tissue Samples.
  Methods in molecular biology (Clifton, N.J.) 2019 Haderk F, Olivas V, Bivona TG
• Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
  Cancer research 2018 Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG
• Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
  Nature medicine 2018 Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, …
• Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
  Clinical lung cancer 2018 Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM
• Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.
  Journal of thoracic disease 2018 Nanjo S, Bivona TG
• Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.
  Journal of cell science 2018 Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL
• Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.
  Science (New York, N.Y.) 2018 Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA
• RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
  Nature cell biology 2018 Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, …
• Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, …
• TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
  The Journal of clinical investigation 2018 Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou…
• Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
  Annals of translational medicine 2018 Zaman A, Bivona TG
• BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.
  JCO precision oncology 2018 Sheikine Y, Pavlick D, Klempner SJ, Trabucco SE, Chung JH, Rosenzweig M, Wang K, Velcheti V, Frampton GM, Peled N, Murray M, Chae YK, Albacker LA, Gay L, Husain H, Suh JH, Millis SZ, Reddy VP, Elvin …
• Oncogenic Signaling Pathways in The Cancer Genome Atlas.
  Cell 2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, …
• The evolving understanding of immunoediting and the clinical impact of immune escape.
  Journal of thoracic disease 2018 McCoach CE, Bivona TG
• Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
  EBioMedicine 2018 Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, …
• Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.
  Cancers 2017 Wu W, Haderk F, Bivona TG
• Imaging PD-L1 Expression with ImmunoPET.
  Bioconjugate chemistry 2017 Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI…
• Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
  Nature genetics 2017 Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero …
• Understanding and targeting resistance mechanisms in NSCLC.
  Nature reviews. Cancer 2017 Rotow J, Bivona TG
• Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.
  Nature communications 2017 Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X, Zhuang G
• Current Landscape of Targeted Therapy in Lung Cancer.
  Clinical pharmacology and therapeutics 2017 Mayekar MK, Bivona TG
• Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
  Nature communications 2017 Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen…
• Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
  Journal of the National Cancer Institute 2017 Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, …
• Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
  Oncotarget 2017 Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R
• A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
  The oncologist 2017 Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK
• Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.
  NPJ precision oncology 2017 Neel DS, Bivona TG
• Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.
  Scientific reports 2017 Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG
• Dividing and conquering the variation among variants in EML4-ALK lung cancer.
  Translational cancer research 2017 Bivona TG
• CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2017 Wang V, Bivona T, Ali SM, Schrock AB, Miller VA
• Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.
  Cancer research 2017 Rho JK, Lee IY, Choi YJ, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, Baek IJ, Lee JY, Ha CH, Sung YH, Kim JK, Kim WS, Song JS, Kim CH, Bivona …
• Metastasis: From head to tail.
  Cell cycle (Georgetown, Tex.) 2017 Okimoto RA, Bivona TG
• Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
  Oncotarget 2016 Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC
• Inactivation of Capicua drives cancer metastasis.
  Nature genetics 2016 Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, …
• Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2016 Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG
• HSP70 dependence in rhabdomyosarcoma: Seed or soil?
  Cell cycle (Georgetown, Tex.) 2016 Sabnis AJ, Bivona TG
• Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma.
  Proceedings of the National Academy of Sciences of the United States of America 2016 Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG
• An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
  Cancer letters 2016 Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, …
• Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
  Clinical lung cancer 2016 McCoach CE, Bivona TG, Blakely CM, Doebele RC
• A framework for understanding and targeting residual disease in oncogene-driven solid cancers.
  Nature medicine 2016 Bivona TG, Doebele RC
• RAS signaling in ALK fusion lung cancer.
  Small GTPases 2016 Hrustanovic G, Bivona TG
• Tracking Down Response and Resistance to TRK Inhibitors.
  Cancer discovery 2016 Okimoto RA, Bivona TG
• RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.
  Molecular & cellular oncology 2015 Hrustanovic G, Bivona TG
• RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
  Nature medicine 2015 Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, …
• Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
  Cancer discovery 2015 Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA
• Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
  Oncogene 2015 Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG
• AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
  Lung Cancer (Auckland, N.Z.) 2015 Okimoto RA, Bivona TG
• The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.
  Molecular & cellular oncology 2015 Lin L, Bivona TG
• AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
  Cancer cell 2015 Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A…
• NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
  Cell reports 2015 Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, …
• AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
  PloS one 2015 Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM
• Adaptive stress signaling in targeted cancer therapy resistance.
  Oncogene 2015 Pazarentzos E, Bivona TG
• The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
  Nature genetics 2015 Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson …
• RAS-MAPK in ALK targeted therapy resistance.
  Cell cycle (Georgetown, Tex.) 2015 Hrustanovic G, Bivona TG
• YAP in MAPK pathway targeted therapy resistance.
  Cell cycle (Georgetown, Tex.) 2015 Flaherty KT, Wargo JA, Bivona TG
• Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.
  Journal of translational medicine 2014 Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B
• Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
  Cancer treatment reviews 2014 Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R
• Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG
• The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M…
• Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues.
  Human mutation 2014 Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C
• Recent advances in personalized lung cancer medicine.
  Personalized medicine 2014 Okimoto RA, Bivona TG
• Genetics and biomarkers in personalisation of lung cancer treatment.
  Lancet (London, England) 2013 Rosell R, Bivona TG, Karachaliou N
• FGFR fusions in the driver's seat.
  Cancer discovery 2013 Sabnis AJ, Bivona TG
• Mechanisms of resistance to EGFR targeted therapies.
  Cancer biology & therapy 2013 Hrustanovic G, Lee BJ, Bivona TG
• Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Neel DS, Bivona TG
• Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
  Cancer discovery 2012 Blakely CM, Bivona TG
• Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.
  Chemotherapy research and practice 2012 Lin L, Bivona TG
• Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
  Nature genetics 2012 Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, …
• Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
  Proceedings of the National Academy of Sciences of the United States of America 2011 Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA
• FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
  Nature 2011 Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL
• Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, …
• Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis.
  Methods in enzymology 2008 Quatela SE, Sung PJ, Ahearn IM, Bivona TG, Philips MR
• PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.
  Molecular cell 2006 Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Pérez de Castro I, Li C, Thompson CB, Cox AD, Philips MR
• Analysis of Ras activation in living cells with GFP-RBD.
  Methods in enzymology 2006 Bivona TG, Quatela S, Philips MR
• Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains.
  Methods (San Diego, Calif.) 2005 Bivona TG, Philips MR
• Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII.
  The Journal of biological chemistry 2005 Jordan JD, He JC, Eungdamrong NJ, Gomes I, Ali W, Nguyen T, Bivona TG, Philips MR, Devi LA, Iyengar R
• Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations.
  The EMBO journal 2004 Walker SA, Kupzig S, Bouyoucef D, Davies LC, Tsuboi T, Bivona TG, Cozier GE, Lockyer PJ, Buckler A, Rutter GA, Allen MJ, Philips MR, Cullen PJ
• Membranes as messengers in T cell adhesion signaling.
  Nature immunology 2004 Dustin ML, Bivona TG, Philips MR
• Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus.
  Molecular and cellular biology 2004 Perez de Castro I, Bivona TG, Philips MR, Pellicer A
• Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.
  Molecular cell 2004 Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG
• Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion.
  The Journal of cell biology 2004 Bivona TG, Wiener HH, Ahearn IM, Silletti J, Chiu VK, Philips MR
• Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK.
  The Journal of biological chemistry 2003 Mohney RP, Das M, Bivona TG, Hanes R, Adams AG, Philips MR, O'Bryan JP
• Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1.
  Nature 2003 Bivona TG, Pérez De Castro I, Ahearn IM, Grana TM, Chiu VK, Lockyer PJ, Cullen PJ, Pellicer A, Cox AD, Philips MR
• Ras pathway signaling on endomembranes.
  Current opinion in cell biology 2003 Bivona TG, Philips MR
• Ras signalling on the endoplasmic reticulum and the Golgi.
  Nature cell biology 2002 Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, Philips MR
• Toxoplasma gondii Rab5 enhances cholesterol acquisition from host cells.
  Cellular microbiology 2002 Robibaro B, Stedman TT, Coppens I, Ngô HM, Pypaert M, Bivona T, Nam HW, Joiner KA